Literature DB >> 3787536

Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation.

S L Hill, H M Morrison, D Burnett, R A Stockley.   

Abstract

The effect of three amoxycillin treatment regimens on purulent secretions of patients with bronchiectasis has been studied. On the basis of information recorded on a diary card the patients were divided into three groups, according to the usual nature of their secretions: seven who produced mucoid sputum, which occasionally became purulent; seven whose secretions were usually mucopurulent but occasionally purulent; and 19 whose secretions were persistently purulent. Treatment with capsules of amoxycillin in a dosage of 250 mg three times a day resulted in clearance of purulent secretions in patients of the mucoid group when they were treated for a clinical exacerbation. The sputum remained clear in these patients for long periods before a further exacerbation (median 6 1/2, range 1-11 months). The mucopurulent-purulent group also responded to this dosage but sputum purulence returned more rapidly (median 9, range 4-31 days). Only three of the 19 (17%) patients with persistently purulent secretions showed a macroscopic response to this dosage, whereas seven (60%) of 12 patients who received the higher dosage (3 g sachets twice a day) responded. Among the failures, some responded to nebulised amoxycillin, suggesting that higher levels of amoxycillin in secretions are required in these patients. Macroscopic clearance of purulent secretions was finally achieved in most of the patients studied. The response was not always predictable from the results of sputum culture. Clearance of secretions by antibiotics was also identified by the patients, using a diary card score. Improvements in well being and in symptoms were noticed even in the group who usually produced mucopurulent and purulent secretions even though they appeared to be clinically stable before treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3787536      PMCID: PMC460390          DOI: 10.1136/thx.41.7.559

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Patterns of distribution and clearance of aerosols in patients with bronchiectasis.

Authors:  R V Lourenço; R Loddenkemper; R W Carton
Journal:  Am Rev Respir Dis       Date:  1972-12

2.  Chronic bronchial sepsis and progressive lung damage.

Authors:  G M Cochrane
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-06

3.  Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state.

Authors:  R A Stockley; S L Hill; H M Morrison
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

4.  Elastolytic activity of sputum and its relation to purulence and to lung function in patients with bronchiectasis.

Authors:  R A Stockley; S L Hill; H M Morrison; C M Starkie
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

5.  Nebulized amoxicillin in chronic purulent bronchiectasis.

Authors:  R A Stockley; S L Hill; D Burnett
Journal:  Clin Ther       Date:  1985       Impact factor: 3.393

6.  Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect.

Authors:  L A Smallman; S L Hill; R A Stockley
Journal:  Thorax       Date:  1984-09       Impact factor: 9.139

7.  A simple oral antimicrobial regimen effective in severe chronic bronchial suppuration associated with culturable Haemophilus influenzae.

Authors:  P J Cole; D E Roberts; S F Davies; R K Knight
Journal:  J Antimicrob Chemother       Date:  1983-02       Impact factor: 5.790

8.  Effect of human leukocyte enzymes on tracheal mucosa and its mucociliary activity.

Authors:  H Tegner; K Ohlsson; N G Toremalm; C von Mecklenburg
Journal:  Rhinology       Date:  1979-09       Impact factor: 3.681

  8 in total
  12 in total

Review 1.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

2.  Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis.

Authors:  I S Woolhouse; S L Hill; R A Stockley
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

3.  Effect of short and long term antibiotic response on lung function in bronchiectasis.

Authors:  S L Hill; R A Stockley
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

4.  Proceedings of the British Thoracic Society. 1986 winter meeting. 11-12 December 1986, London. Abstracts.

Authors: 
Journal:  Thorax       Date:  1987-03       Impact factor: 9.139

5.  Assessment of airway neutrophils by sputum colour: correlation with airways inflammation.

Authors:  R A Stockley; D Bayley; S L Hill; A T Hill; S Crooks; E J Campbell
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

6.  Simple method for quantifying viable bacterial numbers in sputum.

Authors:  A Pye; R A Stockley; S L Hill
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

7.  IgG subclasses in the serum and sputum from patients with bronchiectasis.

Authors:  S L Hill; J L Mitchell; D Burnett; R A Stockley
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

8.  Activities and sources of beta-lactamase in sputum from patients with bronchiectasis.

Authors:  P Dragicevic; S L Hill; D Burnett; D Merrikin; R A Stockley
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

9.  Use of an enzyme-linked immunosorbent assay to assess penetration of amoxicillin into lung secretions.

Authors:  S L Hill; D Burnett; A L Lovering; R A Stockley
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial.

Authors:  Patricia C Valery; Peter S Morris; Keith Grimwood; Paul J Torzillo; Catherine A Byrnes; I Brent Masters; Paul A Bauert; Gabrielle B McCallum; Charmaine Mobberly; Anne B Chang
Journal:  BMC Pediatr       Date:  2012-08-14       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.